CN116870129B - Compound traditional Chinese medicine for warming channel and dredging collaterals for treating reynolds phenomenon related to connective tissue diseases - Google Patents
Compound traditional Chinese medicine for warming channel and dredging collaterals for treating reynolds phenomenon related to connective tissue diseases Download PDFInfo
- Publication number
- CN116870129B CN116870129B CN202311029081.3A CN202311029081A CN116870129B CN 116870129 B CN116870129 B CN 116870129B CN 202311029081 A CN202311029081 A CN 202311029081A CN 116870129 B CN116870129 B CN 116870129B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- blood
- connective tissue
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 44
- 208000018631 connective tissue disease Diseases 0.000 title claims abstract description 22
- 150000001875 compounds Chemical class 0.000 title claims abstract description 21
- 238000010792 warming Methods 0.000 title abstract description 17
- 208000012322 Raynaud phenomenon Diseases 0.000 claims abstract description 17
- 208000003782 Raynaud disease Diseases 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 42
- 239000008280 blood Substances 0.000 abstract description 39
- 210000004369 blood Anatomy 0.000 abstract description 39
- 238000011282 treatment Methods 0.000 abstract description 18
- 230000007812 deficiency Effects 0.000 abstract description 15
- 230000017531 blood circulation Effects 0.000 abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 12
- 201000010099 disease Diseases 0.000 abstract description 11
- 241000758794 Asarum Species 0.000 abstract description 10
- 244000126002 Ziziphus vulgaris Species 0.000 abstract description 9
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract description 8
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract description 8
- 239000009636 Huang Qi Substances 0.000 abstract description 8
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract description 8
- 230000001105 regulatory effect Effects 0.000 abstract description 8
- 208000024891 symptom Diseases 0.000 abstract description 8
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract description 7
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract description 7
- 244000131316 Panax pseudoginseng Species 0.000 abstract description 7
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract description 7
- 244000273928 Zingiber officinale Species 0.000 abstract description 7
- 235000006886 Zingiber officinale Nutrition 0.000 abstract description 7
- 235000008397 ginger Nutrition 0.000 abstract description 7
- 208000006820 Arthralgia Diseases 0.000 abstract description 6
- 241001313857 Bletilla striata Species 0.000 abstract description 6
- 240000007311 Commiphora myrrha Species 0.000 abstract description 6
- 235000006463 Brassica alba Nutrition 0.000 abstract description 5
- 244000140786 Brassica hirta Species 0.000 abstract description 5
- 235000011371 Brassica hirta Nutrition 0.000 abstract description 5
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract description 5
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract description 5
- 235000003956 Luffa Nutrition 0.000 abstract description 5
- 244000050983 Luffa operculata Species 0.000 abstract description 5
- 208000031975 Yang Deficiency Diseases 0.000 abstract description 4
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract description 3
- 235000011477 liquorice Nutrition 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 29
- 230000000144 pharmacologic effect Effects 0.000 description 26
- 230000001737 promoting effect Effects 0.000 description 17
- 210000000952 spleen Anatomy 0.000 description 16
- 238000011160 research Methods 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 12
- 210000004072 lung Anatomy 0.000 description 12
- 210000002784 stomach Anatomy 0.000 description 12
- 239000000126 substance Substances 0.000 description 11
- 239000000796 flavoring agent Substances 0.000 description 10
- 235000019634 flavors Nutrition 0.000 description 10
- 206010062717 Increased upper airway secretion Diseases 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- 230000003213 activating effect Effects 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 8
- 210000002216 heart Anatomy 0.000 description 8
- 208000026435 phlegm Diseases 0.000 description 8
- 241001061264 Astragalus Species 0.000 description 7
- 208000032843 Hemorrhage Diseases 0.000 description 7
- 241001106477 Paeoniaceae Species 0.000 description 7
- 235000006533 astragalus Nutrition 0.000 description 7
- 230000000740 bleeding effect Effects 0.000 description 7
- 150000004676 glycans Chemical class 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 229920001282 polysaccharide Polymers 0.000 description 7
- 239000005017 polysaccharide Substances 0.000 description 7
- 210000004233 talus Anatomy 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 241000180649 Panax notoginseng Species 0.000 description 5
- 235000003143 Panax notoginseng Nutrition 0.000 description 5
- 240000007164 Salvia officinalis Species 0.000 description 5
- 206010042674 Swelling Diseases 0.000 description 5
- 229930003944 flavone Natural products 0.000 description 5
- 235000011949 flavones Nutrition 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 239000000341 volatile oil Substances 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000004957 immunoregulator effect Effects 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 235000017709 saponins Nutrition 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 3
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010062575 Muscle contracture Diseases 0.000 description 3
- 244000236658 Paeonia lactiflora Species 0.000 description 3
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 208000006111 contracture Diseases 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 150000002213 flavones Chemical class 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 230000000004 hemodynamic effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 229940010454 licorice Drugs 0.000 description 3
- 239000010271 massa medicata fermentata Substances 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 208000035824 paresthesia Diseases 0.000 description 3
- 150000002989 phenols Chemical class 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000005412 red sage Nutrition 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241001313855 Bletilla Species 0.000 description 2
- 240000001980 Cucurbita pepo Species 0.000 description 2
- 235000009852 Cucurbita pepo Nutrition 0.000 description 2
- 206010013886 Dysaesthesia Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- 235000017443 Hedysarum boreale Nutrition 0.000 description 2
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 2
- 206010034568 Peripheral coldness Diseases 0.000 description 2
- 235000017276 Salvia Nutrition 0.000 description 2
- 229930183118 Tanshinone Natural products 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 2
- 235000006545 Ziziphus mauritiana Nutrition 0.000 description 2
- 235000008529 Ziziphus vulgaris Nutrition 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 229940107666 astragalus root Drugs 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 244000132619 red sage Species 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 210000003371 toe Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 1
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 1
- MZLKNWMNBXHXMA-UHFFFAOYSA-N 1-phenylheptylbenzene Chemical compound C=1C=CC=CC=1C(CCCCCC)C1=CC=CC=C1 MZLKNWMNBXHXMA-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- QQUHMASGPODSIW-UHFFFAOYSA-N Albiflorin Natural products C=1C=CC=CC=1C(=O)OCC12C(=O)OC3(C)CC(O)C1CC32OC1OC(CO)C(O)C(O)C1O QQUHMASGPODSIW-UHFFFAOYSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241001289295 Asarum sieboldii Species 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 241001481833 Coryphaena hippurus Species 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 241000732800 Cymbidium Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 208000009849 Female Genital Neoplasms Diseases 0.000 description 1
- 206010060710 Galactostasis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 244000280244 Luffa acutangula Species 0.000 description 1
- 235000009814 Luffa aegyptiaca Nutrition 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 241001057584 Myrrha Species 0.000 description 1
- 240000009023 Myrrhis odorata Species 0.000 description 1
- NEEQFPMRODQIKX-REOHCLBHSA-N N(3)-oxalyl-L-2,3-diaminopropionic acid Chemical compound OC(=O)[C@@H](N)CNC(=O)C(O)=O NEEQFPMRODQIKX-REOHCLBHSA-N 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 241000220261 Sinapis Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- 206010040893 Skin necrosis Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- QQUHMASGPODSIW-ICECTASOSA-N albiflorin Chemical compound O([C@@]12C[C@H]3[C@H](O)C[C@@]1(OC(=O)[C@]32COC(=O)C=1C=CC=CC=1)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QQUHMASGPODSIW-ICECTASOSA-N 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229910052956 cinnabar Inorganic materials 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- XXPBFNVKTVJZKF-UHFFFAOYSA-N dihydrophenanthrene Natural products C1=CC=C2CCC3=CC=CC=C3C2=C1 XXPBFNVKTVJZKF-UHFFFAOYSA-N 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004401 flow injection analysis Methods 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 229940102465 ginger root Drugs 0.000 description 1
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 1
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 1
- 235000002780 gingerol Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 150000002987 phenanthrenes Chemical class 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 229930015704 phenylpropanoid Natural products 0.000 description 1
- 150000002995 phenylpropanoid derivatives Chemical class 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 229930183842 salvianolic acid Natural products 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000001841 zingiber officinale Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
- A61K36/268—Asarum (wild ginger)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A compound Chinese medicine for treating connective tissue disease related Raynaud phenomenon, warming channel and dredging collaterals, belongs to the technical field of compound Chinese medicine preparation. The compound traditional Chinese medicine for warming channel and invigorating pulse is composed of 15-24 parts of radix astragali Preparata, 5-15 parts of cassia twig, 1-5 parts of asarum, 5-15 parts of white paeony root, 10-15 parts of radix salviae miltiorrhizae, 2-5 parts of myrrh, 1-3 parts of pseudo-ginseng, 8-15 parts of bletilla striata, 5-12 parts of white mustard seed, 10-14 parts of luffa, 5-15 parts of medicated leaven, 3-8 parts of ginger, 10-18 parts of jujube and 5-12 parts of liquorice. The disease is the symptoms of the deficiency and the excess, the deficiency of qi and yang is the root, and the stagnation of qi and blood stasis are the symptoms. The yang deficiency causes the weakness of the pulse, which is liable to cause qi stagnation and blood circulation retardation, and the obstruction of the collaterals can induce or aggravate the illness. Therefore, the invention selects the medicines for common use, has the effects of invigorating qi, warming channels, regulating blood and removing arthralgia, and is integrally combined with the medicines to strengthen superficies without retaining evil or dispelling evil without damaging the vital qi and the evil and the vital qi. Has better treatment effect on the Raynaud phenomenon related to connective tissue diseases.
Description
Technical Field
The invention belongs to the technical field of compound traditional Chinese medicine preparations, and particularly relates to a meridian warming and dredging compound traditional Chinese medicine for treating reynolds phenomenon related to connective tissue diseases.
Background
Connective tissue disease-related Raynaud's phenomenons (Raynaud's) is a circulatory disorder characterized by vasospasms in the cold or mood changes of the fingers, toes or other outer limbs, resulting in temporary interruption of blood supply, causing ischemia and symptoms. In connective tissue diseases, reynolds phenomenon is often one of the early symptoms, especially systemic lupus erythematosus and systemic sclerosis. The pathological characteristics of the composition relate to the aspects of abnormal reaction of blood vessels, inflammation, abnormal immune system and the like. Different connective tissue diseases have different incidences of reynolds phenomena; about 60% to 90% of MCTD patients develop reynolds, which is very common in scleroderma patients, with about 15-30% of SLE patients accompanied by reynolds, with an estimated incidence of 70% -90%.
Connective tissue disease-related reynolds phenomenon itself does not generally pose a direct hazard to life, but it may cause some discomfort and potential complications. At the onset of Raynaud's phenomenon, the affected fingers, toes or other outer limbs may feel pain, tingling, numbness and irritation. Under severe reynolds conditions, hypoxia and injury may occur. Long-term recurrent attacks can cause skin ulcers, necrosis and tissue degeneration, even with infection; persistent pain, discomfort and limited activity may lead to anxiety, depression and reduced quality of life.
In the past, the effective diagnosis and treatment means for the diseases are lacking, the patients cannot recognize the diseases sufficiently, and the patients cannot pay attention to the diseases in early stage, so that the optimal treatment time is delayed; the current western medicine treatment mainly relieves symptoms and improves blood circulation through medicines, however, the medicines can only provide temporary relief and cannot fundamentally cure Raynaud phenomenon. Some side effects may occur in the treatment of Raynaud's phenomenon with certain drugs, for example, calcium antagonists may cause adverse effects such as headache, hypotension and palpitations. Because western medicines have great side effects, people have great demands for traditional Chinese medicine medicines for effectively treating Raynaud phenomena related to connective tissue diseases.
Disclosure of Invention
Aiming at the defects of the existing western medicine treatment medicines and means, the technical problem to be solved by the invention is to provide the meridian warming and vein relaxing compound traditional Chinese medicine for treating the reynolds phenomenon related to connective tissue diseases.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
a compound Chinese medicine for treating the Raynaud phenomenon related to connective tissue diseases comprises the following Chinese medicine raw materials in parts by weight:
in the compound traditional Chinese medicine for treating the Raynaud phenomenon related to connective tissue diseases, the efficacy of each traditional Chinese medicine is as follows:
radix astragali Preparata, also known as radix astragali, radix astragali. Sweet in flavor and slightly warm in nature. Enter lung and spleen meridians. Has effects of invigorating spleen, invigorating middle warmer, invigorating yang, consolidating superficial resistance, promoting urination, removing toxic substances, and promoting granulation. It is indicated for spleen qi deficiency, lung qi deficiency, spontaneous perspiration due to qi deficiency, qi and blood deficiency, and sores and ulcers, or chronic ulcer. Modern pharmacological studies have shown that astragalus contains a variety of active ingredients, such as astragalus polysaccharides, astragalus saponins, astragalus flavones, etc., wherein the immunoregulatory effect of astragalus polysaccharides is considered as one of the most important effects.
Ramulus Cinnamomi, also known as ramulus Cinnamomi tip, ramulus Cinnamomi. Pungent and sweet in flavor and warm in nature. It enters heart, lung and bladder meridians. Has effects in inducing sweat, relieving muscular tension, warming and activating meridian, supporting yang, activating qi-flowing, and calming the pulse. Can be used for treating common cold due to wind-cold, abdominal pain, amenorrhea due to blood cold, arthralgia, phlegm retention, edema, palpitation, and dolphin. Modern pharmacological researches show that cassia twig contains various chemical components including volatile components, organic acids, glycosides and the like, and domestic and foreign literature researches mainly focus on cinnamaldehyde and cinnamic acid, and mainly have pharmacological effects of regulating body temperature, easing pain, inhibiting bacteria, resisting inflammation, resisting allergy, resisting viruses, promoting vasodilation, promoting urination, calming, resisting anxiety, resisting tumors, reducing blood pressure and the like.
Asarum, also known as asarum sieboldii, asarum pentadactyla, asarum decumbens. Pungent and warm in nature. It enters heart, lung and kidney meridians. Has effects of relieving exterior syndrome, dispelling cold, dispelling pathogenic wind, relieving pain, inducing resuscitation, warming lung, and resolving fluid retention. Modern pharmacological researches have shown that asarum has various chemical components, wherein volatile oil is related to the effects of dispelling cold and relieving fever, relieving pain and inflammation, resisting allergy and the like, and is also a toxic component. The asarum also contains lignans, flavonoids, amides, alkaloids, phenanthrenes and other non-volatile oil components, which play an important role in regulating immunity, resisting inflammation, relieving pain, strengthening heart, dilating blood vessels and the like.
Bai Shao is bitter in flavor, sour and slightly cold in nature. Enter liver and spleen meridians. Has effects of nourishing blood, regulating menstruation, astringing yin, suppressing sweating, softening liver, relieving pain, and suppressing liver yang. Modern pharmacological research shows that the chemical components of white peony root mainly comprise paeoniflorin, albiflorin, paeoniflorin oxide and the like. Particularly, the research on the total glucosides of white paeony is focused, and the white paeony has the effects of immunoregulation, anti-inflammation, liver protection and the like, and also has the effects of brain and nerve protection, cardiovascular protection, kidney protection, cell proliferation inhibition and the like, and has good application and development prospects.
Red sage root, red ginseng and goat milk. Bitter taste and slightly cold nature. It enters heart and liver meridians. Has effects of promoting blood circulation, removing blood stasis, dredging channels, relieving pain, clearing heart fire, relieving restlessness, cooling blood, and resolving carbuncle. Is mainly used for treating chest stuffiness and pain, pain in the stomach and abdomen and hypochondrium, mass, pain in the hot stuffiness, vexation and insomnia, irregular menstruation, dysmenorrhea and amenorrhea, and sore pain. Modern pharmacological studies show that the chemical components of red sage root are mainly divided into tanshinones as liposoluble component and salvianolic acids as water-soluble component. The salvia miltiorrhiza has wide and complex pharmacological activity, and the main pharmacological activity of tanshinone fat-soluble components is anticoagulation, platelet aggregation resistance, blood lipid regulation, inflammation resistance and tumor resistance; the main pharmacological activity of the phenolic acid water-soluble component is antioxidation, antiatherosclerosis and antihypertensive; in addition, the red sage polysaccharide has obvious antitumor and immunoregulating effects.
Myrrh, known as powder, ming Yao, is pungent and bitter in flavor and neutral in nature. It enters heart, liver and spleen meridians. Has effects of removing blood stasis, relieving pain, relieving swelling, and promoting granulation. Is mainly used for treating chest stuffiness and pain, epigastric pain, dysmenorrhea, amenorrhea, postpartum stasis, abdominal pain, rheumatalgia, traumatic injury, carbuncle, swelling and ulcer. Modern pharmacological studies show that the main chemical components of myrrh include monoterpenes, sesquiterpenes, triterpenes, steroids, lignin, etc. Has pharmacological activities in various aspects such as antipyresis, anti-inflammatory, pain relieving, anti-tumor, blood fat reducing, nerve protection and the like, and has no obvious toxic or side effect.
Notoginseng radix, also known as Notoginseng radix, radix Stephaniae Sinicae, has sweet and slightly bitter taste, and enters the liver, stomach and large intestine meridians. Has the effects of enriching blood, removing blood stasis, stopping bleeding and stopping bleeding, can promote the circulation of qi and tonify, has the best effect, and is the most precious one in the prescription. Notoginseng radix has effects of removing blood stasis, promoting tissue regeneration, stopping bleeding, and promoting blood circulation without damaging new blood, and can be used for treating traumatic blood stasis, traumatic hemorrhage, puerperal blood dizziness, hematemesis, and epistaxis; the cooked Notoginseng radix powder has effects of tonifying deficiency and strengthening body, and can be used for treating asthenia, anorexia, neurasthenia, excessive fatigue, blood loss, anemia, etc. Modern pharmacological researches show that the active ingredients of the pseudo-ginseng mainly comprise pseudo-ginseng total saponins, dencichine, pseudo-ginseng polysaccharide and the like, and the active ingredients have wide application in the treatment of various clinical diseases such as ophthalmic diseases, orthopedic diseases, coronary heart disease angina, gynecological tumors and the like, and the main effects of the active ingredients include anti-tumor, blood flow increasing, vasodilation, microcirculation improvement, treatment or prevention of heart and brain tissue hypoxia ischemia, blood pressure reduction, hemostasis and the like.
Bletilla striata, rhizoma bletilla, rhizoma coptidis, radix glycyrrhizae, rhizoma polygonati, indocalami, cinnabar, violet, cymbidium, and radix baeri. Bitter, sweet and astringent in flavor, slightly cold in nature. It enters lung, liver and stomach meridians. Has effects of astringing, stopping bleeding, detumescence and promoting granulation. Is mainly used for hemoptysis, hematemesis, traumatic hemorrhage, pyocutaneous disease, pyogenic infections and chapped skin. Modern pharmacological researches have found that bletilla striata mainly comprises bibenzyl, dihydrophenanthrene, phenanthrene and derivatives thereof, and contains a small amount of volatile oil, polysaccharide, starch, glucose and the like. The main pharmacological activities include resisting pathogenic microorganism, stopping bleeding, promoting blood circulation, resisting tumor, promoting wound healing, resisting gastric ulcer, and regulating immunity.
Semen Sinapis Albae, also known as Hu Gai, semen Sinapis Albae. Pungent in flavor and warm in nature, enter lung and stomach meridians. Has effects of warming lung, eliminating phlegm, activating qi-flowing, resolving hard mass, dredging collaterals and relieving pain. Is mainly used for treating cold disease, asthma and cough, chest and hypochondrium distending pain, phlegm stagnation, meridian joint numbness, phlegm-dampness flow injection, yin carbuncle and swelling toxin and the like. Modern pharmacological researches show that white mustard seed mainly contains polysaccharide, volatile oil, fatty acid, alkaloid and flavone 5, and the chemical components are mainly fatty acid. Semen Sinapis Albae contains abundant fatty acid and fatty acid methyl ester, and oleic acid and erucic acid are used as main materials. Pharmacological studies have focused on anti-inflammatory, analgesic, antitussive, expectorant, antiasthmatic, and transdermal absorption.
Retinervus Luffae fructus, sweet in taste and neutral in nature. It enters lung, stomach and liver meridians. Has effects of dispelling pathogenic wind, dredging collaterals, promoting blood circulation, and promoting lactation. It is mainly used for arthralgia, contracture, distending pain in chest and hypochondrium, galactostasis, and acute mastitis. Modern researches have shown that luffa is rich in triterpenes and saponins, flavones and phenols, oils and organic acids, proteins and other chemical components, and has pharmacological effects of inducing diuresis, relieving swelling, relieving inflammation and pain, lowering blood sugar and blood lipid, resisting oxidation, regulating immunity and resisting cancer. In recent years, with the intensive research of chemical components and pharmacological actions of towel gourd, the clinical application range of the towel gourd is expanding.
Massa Medicata Fermentata, and Massa Medicata Fermentata are sweet and pungent in taste and. Enter spleen and stomach meridians. Has effects of invigorating spleen, regulating stomach function, promoting digestion, and resolving food stagnation. Is mainly used for treating food stagnation, dyspepsia, abdominal distention, inappetence, emesis and diarrhea. Modern pharmacological research shows that medicated leaven is rich in phenolic components (flavone, phenylpropanoid, coumarin, etc.), saccharomycetes, amylase, vitamin B complex, ergosterol, protein, fat, volatile oil, etc. The phenols mainly comprise Massa Medicata Fermentata total phenols, and have antioxidant, antiinflammatory, and immunoregulatory effects.
Ginger, ginger root, bai La Yun, collude the finger, di Xin, yan Liang Xiao Zi, pungent in flavor and slightly warm in nature. Enter lung, spleen and stomach meridians. Has effects of relieving exterior syndrome, dispelling cold, warming middle energizer, relieving vomiting, eliminating phlegm, relieving cough, and relieving fish and crab toxin. Is mainly used for treating wind-cold type common cold, gastric cold vomiting, cough with cold phlegm and poisoning of fish and crabs. Modern pharmacological researches have shown that the main chemical components of ginger comprise volatile oil, gingerol, diphenylheptane and the like, and have pharmacological activities of resisting tumor, resisting oxidation, relieving vomiting, resisting inflammation, inhibiting bacteria and the like.
Jujube, sweet in flavor and warm in nature. It enters spleen, stomach and heart meridians. Has effects of invigorating spleen and replenishing qi, nourishing blood and tranquillizing. Modern pharmacological researches have found that the researches on chemical components of Chinese dates mainly focus on components such as three mushroom acids, saponins, alkaloids, flavones and glycosides. The jujube has multiple pharmacological activities, can strengthen immunity, inhibit cancer cell proliferation, protect liver, resist type I allergic reaction and other wide pharmacological actions, has certain curative effects on hypertension, diabetes, cardiogenic shock and the like, and is a traditional medicine and food dual-purpose food.
Licorice root, radix Glycyrrhizae enters heart, lung, spleen and stomach meridians. Has effects of invigorating spleen, replenishing qi, clearing heat, detoxicating, eliminating phlegm, relieving cough, relieving spasm, relieving pain, and harmonizing the medicines. Is mainly used for treating weakness of spleen and stomach, lassitude, palpitation, shortness of breath, cough with excessive phlegm, epigastric and abdominal contracture, pain, carbuncle, swelling and sore toxin, and relieving drug toxicity and intensity. Modern pharmacological studies show that the chemical components of licorice mainly comprise triterpene saponins, flavonoids, licorice polysaccharides and the like. Pharmacological actions of licorice mainly include anti-inflammatory, anti-tumor, antibacterial, antiviral, antioxidant and immunoregulatory actions.
The traditional Chinese medicine considers that qi deficiency and blood stasis and yang deficiency and cold excess are main factors for the pathogenesis of Raynaud's disease, and the qi deficiency and blood stasis and the yang deficiency and cold excess are classified as blood arthralgia. The patients have insufficient essence body, yang qi deficiency, qi and blood deficiency, blood vessel deficiency cold, secondary cold and exogenous evil, cold coagulation and blood stasis, and refers to malnutrition of the extremities and contracture of the meridians. "Su Wen-Baotong Lun" is: cold qi entering the channel is delayed and is not performed. Cold pathogen is caused by external pathogenic factors and external pathogenic factors, which cause the disease of qi and blood stasis in the collaterals. The disease is the pattern of the principal deficiency and the secondary excess, the deficiency of qi and yang is the principal, and the stagnation of qi and blood stasis is the secondary aspect. The yang deficiency is the weakness of the drum, which is easy to cause qi movement retardation and blood circulation retardation, and the venation obstruction can induce or aggravate illness, common symptoms are cold hands and feet, cyanosis, pain and the like, so the meridian warming and vein relaxing agent can be added at the same time. Therefore, the invention provides a compound traditional Chinese medicine for treating the reynolds phenomenon related to connective tissue diseases, which is prepared from radix astragali preparata, cassia twig, asarum, white paeony root, root of red-rooted salvia, myrrh, pseudo-ginseng, bletilla striata, white mustard seed, luffa, medicated leaven, ginger, jujube and liquorice, and can effectively treat the reynolds phenomenon related to connective tissue diseases.
In the traditional Chinese medicine compound, astragalus and cassia twig are used as monarch, astragalus Gan Wenyi qi is used for supplementing defensive qi in the exterior; gui Zhi is pungent and sweet in nature and warm in nature, and has the functions of warming meridians and activating collaterals, dispelling cold evil. The two are mutually supported, and the ramulus cinnamomi has the effect of tonifying qi of the radix astragali and can excite the weiyang, and the radix astragali has the effect of reinforcing the exterior without retaining evil. Asarum, white paeony root, red-rooted salvia root, myrrh and pseudo-ginseng are used as ministers; asarum herb is pungent and warm in nature, and can warm the channels and promote the circulation of blood, warm viscera internally, and promote the circulation of cinnamon twig externally and promote the warming of channels, dispelling cold and relieving pain. White peony root, radix Paeoniae alba is used to treat arthralgia due to its exclusive use in liver and spleen, to soften liver and relieve pain, to nourish blood and regulate nutrient and to promote blood circulation, and to regulate nutrient and defensive qi and exterior and interior. Danshen is bitter in flavor and can dispel heat, clear slightly cold energy, and combined with myrrh to exert the actions of activating blood and removing stasis to unblock meridians and stop pain, and prevent pungent and warm nature from being too dry and drastic, consuming yin and blood. Notoginseng radix is slightly bitter and has effects of relieving pain, nourishing and promoting digestion, and has effects of both middle warmer and middle warmer, stopping bleeding and removing blood stasis, and tonifying deficiency, and has effects of stopping bleeding without blood stasis, promoting blood circulation without consuming qi, and preventing excessive blood circulation of Saviae Miltiorrhizae radix and Myrrha. Bletilla striata, white mustard seed, loofah sponge, medicated leaven, ginger and jujube are used as adjuvant drugs; the flavor of bletilla is bitter and astringent, and slightly cold, so as to prevent excessive consumption of qi and yin. Semen Sinapis Albae is pungent and warm in nature, and is specially used for treating lung meridian, activating qi-flowing in the body, and has effects of activating qi-flowing, resolving hard mass, dredging collaterals, and relieving pain. The luffa body has the effects of dispelling wind and dredging collaterals, promoting blood circulation and activating qi-flowing, and assisting the white paeony root in nourishing nutrient blood and dredging four powders. Spleen and stomach are the source of qi and blood biochemistry, so medicated leaven, chinese date, astragalus root and white paeony root are added to invigorate spleen and stomach, nourish blood and replenish qi, and the middle energizer is transported, so that qi and blood can be biochemically active, so as to obtain the functions of astragalus root and white paeony root; ginger, rhizoma Zingiberis recens, with pungent and warm nature, can dispel pathogenic wind, helps the action of ramulus Cinnamomi and retinervus Luffae fructus to both with jujube and with ying and wei. Licorice root, radix Glycyrrhizae also regulates the actions of other drugs and acts as a guiding drug.
The above medicines are used together, so that the effects of invigorating qi, warming channels, regulating blood and removing arthralgia are achieved, and the whole recipe is compatible with the effects of strengthening exterior without retaining evil or dispelling evil without damaging the body resistance, and the evil and the body resistance are considered. Has better treatment effect on the Raynaud phenomenon related to connective tissue diseases.
As a preferable technical scheme of the invention, the effective components are preferably prepared from the following traditional Chinese medicine raw materials in parts by weight:
as a preferable technical scheme of the invention, the effective components are further preferably prepared from the following traditional Chinese medicine raw materials in parts by weight:
the compound traditional Chinese medicine for treating the reynolds phenomenon related to connective tissue diseases can be prepared into decoction, gel paste, ointment, tablets, capsules, granules, dripping pills, oral liquid, pills, syrup, dispersible tablets or effervescent tablets according to the conventional preparation method of the traditional Chinese medicine compound. The prepared traditional Chinese medicine decoction has the best administration effect.
Drawings
Figure 1 compares the symptom scores (skin temperature, pain, and dysesthesia) of the two groups of patients before and after treatment.
Figure 2 compares the hemodynamic parameters (hemodynamic parameters peak systolic velocity, end diastolic blood flow velocity, resistance index) of the two groups of patients before and after treatment.
Figure 3 comparison of the microcirculation integral of the nail folds of the two groups of patients before and after treatment.
Detailed Description
The compound traditional Chinese medicine for treating the Raynaud phenomenon related to connective tissue diseases for warming channel and dredging collaterals is further described in detail below with reference to the accompanying drawings and examples.
Example 1
Mixing 20g of radix astragali Preparata, 9g of cassia twig, 3g of asarum, 12g of white peony root, 12g of radix salviae miltiorrhizae, 3g of myrrh, 3g of pseudo-ginseng, 12g of bletilla striata, 8g of white mustard seed, 12g of luffa, 12g of medicated leaven, 5g of ginger, 15g of jujube and 8g of liquorice, adding 400g of water, heating and refluxing for extraction, filtering, adding 250g of water again, heating and refluxing for extraction. Combining the two filtrates, and concentrating to obtain about 400mL decoction.
Example 2
The compound retrospective clinical study is carried out, and patients with the reynolds phenomenon are taken in the first affiliated hospital 2021 to 2023 of Anhui university of traditional Chinese medicine, and the compound retrospective clinical study is orally taken by the decoction (prepared in example 1) 200mL each time, 2 times a day and 4 weeks of treatment course. A total of 30 patients were enrolled.
The results of the study found that the patient symptom score (skin temperature, pain, dysesthesia) was significantly reduced (P < 0.05) after treatment compared to before treatment (see fig. 1); the Peak Systolic Velocity (PSV), end diastolic blood velocity (EDV) of the hemodynamic parameters on the palmar side of the patient after treatment were significantly increased (P < 0.05), and the resistance index (ri= (PSV-EDV)/PSV) was significantly decreased (P < 0.05) (see fig. 2); the integration of the nail fold microcirculation was significantly reduced (P < 0.05) after treatment compared to before treatment (see fig. 3).
Therefore, the compound traditional Chinese medicine for warming channels and dredging collaterals provided by the invention can be used for treating the Raynaud phenomenon related to connective tissue diseases, and has good treatment effect.
The foregoing is merely illustrative and explanatory of the principles of the invention, as various modifications and additions may be made to the specific embodiments described, or similar thereto, by those skilled in the art, without departing from the principles of the invention or beyond the scope of the appended claims.
Claims (3)
1. The compound traditional Chinese medicine for treating the Raynaud phenomenon related to connective tissue diseases is characterized by comprising the following effective components in parts by weight:
2. the compound traditional Chinese medicine for treating connective tissue disease-related Raynaud phenomenon, which is disclosed in claim 1, is characterized in that the effective components are prepared from the following traditional Chinese medicine raw materials in parts by weight:
3. the compound traditional Chinese medicine for treating connective tissue disease-related Raynaud phenomenon, which is disclosed in claim 2, is characterized in that the effective components are prepared from the following traditional Chinese medicine raw materials in parts by weight:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311029081.3A CN116870129B (en) | 2023-08-16 | 2023-08-16 | Compound traditional Chinese medicine for warming channel and dredging collaterals for treating reynolds phenomenon related to connective tissue diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311029081.3A CN116870129B (en) | 2023-08-16 | 2023-08-16 | Compound traditional Chinese medicine for warming channel and dredging collaterals for treating reynolds phenomenon related to connective tissue diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116870129A CN116870129A (en) | 2023-10-13 |
| CN116870129B true CN116870129B (en) | 2024-03-26 |
Family
ID=88266480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311029081.3A Active CN116870129B (en) | 2023-08-16 | 2023-08-16 | Compound traditional Chinese medicine for warming channel and dredging collaterals for treating reynolds phenomenon related to connective tissue diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116870129B (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6444681B1 (en) * | 2000-06-09 | 2002-09-03 | The Ohio State University Research Foundation | Methods and compositions for treating Raynaud's Phenomenon and scleroderma |
| CN101041052A (en) * | 2007-04-20 | 2007-09-26 | 于振鹏 | Chinese traditional medicine compound took orally for treating Raynand's disease |
| CN101569664A (en) * | 2008-04-30 | 2009-11-04 | 刘家俊 | Traditional Chinese medicine for treating Raynaud's disease |
| CN101690762A (en) * | 2009-02-24 | 2010-04-07 | 刘文章 | Oral preparation for curing nerve ending diseases and Raynaud disease |
| CN105362452A (en) * | 2014-08-29 | 2016-03-02 | 李敏 | Medicine for treating Raynaud disease |
| CN105561272A (en) * | 2016-01-27 | 2016-05-11 | 赵俊 | Traditional Chinese medicine preparation for relieving Reynolds disease and preparation method thereof |
| CN105920564A (en) * | 2016-06-24 | 2016-09-07 | 卢航 | Traditional Chinese medicinal decoction for treating raynaud syndrome |
| CN114159530A (en) * | 2020-09-11 | 2022-03-11 | 鲁南制药集团股份有限公司 | Application of Mailuoshutong preparation in preparation of medicine for treating Raynaud syndrome |
-
2023
- 2023-08-16 CN CN202311029081.3A patent/CN116870129B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6444681B1 (en) * | 2000-06-09 | 2002-09-03 | The Ohio State University Research Foundation | Methods and compositions for treating Raynaud's Phenomenon and scleroderma |
| CN101041052A (en) * | 2007-04-20 | 2007-09-26 | 于振鹏 | Chinese traditional medicine compound took orally for treating Raynand's disease |
| CN101569664A (en) * | 2008-04-30 | 2009-11-04 | 刘家俊 | Traditional Chinese medicine for treating Raynaud's disease |
| CN101690762A (en) * | 2009-02-24 | 2010-04-07 | 刘文章 | Oral preparation for curing nerve ending diseases and Raynaud disease |
| CN105362452A (en) * | 2014-08-29 | 2016-03-02 | 李敏 | Medicine for treating Raynaud disease |
| CN105561272A (en) * | 2016-01-27 | 2016-05-11 | 赵俊 | Traditional Chinese medicine preparation for relieving Reynolds disease and preparation method thereof |
| CN105920564A (en) * | 2016-06-24 | 2016-09-07 | 卢航 | Traditional Chinese medicinal decoction for treating raynaud syndrome |
| CN114159530A (en) * | 2020-09-11 | 2022-03-11 | 鲁南制药集团股份有限公司 | Application of Mailuoshutong preparation in preparation of medicine for treating Raynaud syndrome |
Non-Patent Citations (7)
| Title |
|---|
| 中西医结合治疗雷诺综合征31例;戴广珠;;实用中医药杂志;-;20131015;第-卷(第10期);第842页 * |
| 刘东汉教授运用当归四逆汤经验举隅;杰;刘喜平;;中医研究;-;20160110;第-卷(第01期);第30-32页 * |
| 参附注射液合当归四逆汤化裁治疗雷诺综合征32例;刘英华;伍德军;邓玉艳;;广西中医药;-;20070820;第-卷(第04期);第49页 * |
| 基于文献的雷诺病中医治疗方药的数据分析;樊炜静;付常庚;李鹏;孙武;王品一;杨宝钟;;中国中医急症;20181115(第11期);第180-183页 * |
| 当归四逆汤加减治愈雷诺氏病;魏军平;四川中医;-;19910915;第-卷(第09期);第38-39页 * |
| 治疗血液病常用药对应用经验;温楚楚;陈瑶;李达;;环球中医药;20201006(第10期);第124-126页 * |
| 经方临床运用;李良标，叶益丰;河南中医;-;19950820;第-卷(第04期);第214页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116870129A (en) | 2023-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100643880B1 (en) | Composition of medicinal herbs for treating rhinitis, empyema, bronchitis and tympanitis | |
| CN101391077B (en) | Preparation method of traditional Chinese medicine for treating chronic pelvic inflammatory disease | |
| CN103041312A (en) | Traditional Chinese medicine composition with antineoplastic effect and preparation method and application thereof | |
| CN104138550A (en) | Preparation method of medicine for treating peptic ulcers | |
| CN103432559B (en) | Traditional Chinese medicine composition for treating spanomenorrhea and dysmenorrhea caused by blood stasis and preparation method and application thereof | |
| CN101095923A (en) | Chinese traditional medicine for treating ectopic pregnancy | |
| CN102512559B (en) | Chinese medicinal composition for treating scapulohumeral periarthritis | |
| CN115282229B (en) | Traditional Chinese medicine composition for treating qi deficiency and blood stasis type coronary heart disease and preparation method thereof | |
| CN103505530B (en) | Traditional Chinese medicine composition for treating variability measles | |
| CN116870129B (en) | Compound traditional Chinese medicine for warming channel and dredging collaterals for treating reynolds phenomenon related to connective tissue diseases | |
| CN104689132A (en) | Traditional Chinese medicine composition for treating psoriasis | |
| CN102772534A (en) | Traditional Chinese medicine ointment for treating hemorrhoids | |
| CN112691157A (en) | Formula and preparation method of medicinal material composition for treating rheumatic arthritis | |
| CN104645163A (en) | Traditional Chinese medicine composition for treating psoriasis | |
| CN105106634A (en) | Traditional Chinese medicine preparation for treating acute appendicitis and application thereof | |
| CN106074912B (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases | |
| CN105727156A (en) | Cancer inhibiting and pain relieving cataplasm and preparation method thereof | |
| CN115120690B (en) | Traditional Chinese medicine composition for treating precocious puberty and application thereof | |
| CN104338052A (en) | Formula of traditional Chinese medicine for treating cerebral thrombosis | |
| CN111084842B (en) | External traditional Chinese medicine composition for treating scapulohumeral periarthritis, cervical spondylosis, lumbar disc herniation and osteoarthritis | |
| CN101897908B (en) | Traditional Chinese medicine composition for treating cirrhosis ascites and liver cancer and preparation method thereof | |
| CN105596592A (en) | Postpartum care type traditional Chinese medicine | |
| CN104688916A (en) | TCM (Traditional Chinese Medicine) composition for treating psoriasis | |
| CN104689254A (en) | Traditional Chinese medicine composition for treating psoriasis | |
| CN104645224A (en) | Traditional Chinese medicine preparation for treating costal chondritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |